×
Biomerica EBIT 2010-2024 | BMRA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Biomerica ebit from 2010 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Biomerica EBIT 2010-2024 | BMRA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Biomerica ebit from 2010 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$74.8B
Chugai Pharmaceutical (CHGCY)
$70.2B
Takeda Pharmaceutical (TAK)
$41.1B
Sandoz Group AG (SDZNY)
$19.6B
Merck (MKKGY)
$18.8B
Astellas Pharma (ALPMY)
$17.3B
United Therapeutics (UTHR)
$16B
Neurocrine Biosciences (NBIX)
$14.5B
Summit Therapeutics (SMMT)
$14B
Shionogi (SGIOY)
$12.1B
Orion OYJ (ORINY)
$7.2B
Stevanato Group S.p.A (STVN)
$6.9B
Madrigal Pharmaceuticals (MDGL)
$6.4B
Corcept Therapeutics (CORT)
$5.8B
Hikma Pharmaceuticals Plc (HKMPF)
$5.5B
Grifols, S.A (GRFS)
$5B
Ionis Pharmaceuticals (IONS)
$5B
Crinetics Pharmaceuticals (CRNX)
$3.5B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Recursion Pharmaceuticals (RXRX)
$2.6B
NewAmsterdam Pharma (NAMS)
$2.2B
Soleno Therapeutics (SLNO)
$2B
Centessa Pharmaceuticals (CNTA)
$2B
Hypermarcas (HYPMY)
$1.9B
Indivior (INDV)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.5B
Evotec AG (EVO)
$1.5B
Dyne Therapeutics (DYN)
$1.4B
Xencor (XNCR)
$1.3B